PRTFDC1 Protein (His Tag)

14.03.2013

Sino Biological Inc. liefert PRTFDC1 Protein (His Tag) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über PRTFDC1 Protein (His Tag) lesen Sie bitte: http://www.sinobiological.com/PRTFDC1-Protein-g-10607.html

Produkt-Information von PRTFDC1 Protein

Synonym	PRTFDC1, HHGP
Protein Construction	A DNA sequence encoding the mature form of human PRTFDC1 (Q9NRG1-1) (Met1-Val225) was expressed with a polyhistide tag at the N-terminus.
Source	Human
Expression Host	E.coli

QC Testing von PRTFDC1 Protein

Purity	> 95 % as determined by SDS-PAGE	SDS-PAGE: PRTFDC1 protein
Endotoxin	Please contact us for more information.
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	His
Molecular Mass	The recombinant human PRTFDC1 consists of 240 amino acids and predicts a molecular mass of 27.5 KDa. It migrates as an approximately 19 KDa band in SDS-PAGE under reducing conditions.
Formulation	Lyophilized from sterile 50mM Tris, 10% glycerol, PH 8.0. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide von PRTFDC1 Protein

Storage	Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage.Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Beschreibung von PRTFDC1 Protein

PRTFDC1 is a member of the purine/pyrimidine phosphoribosyltransferase family. It can bind GMP, IMP and alpha-D-5-phosphoribosyl 1-pyrophosphate (PRPP). The epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island leads to a loss of PRTFDC1 function, which might be involved in squamous cell oral carcinogenesis. PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse and has important implications for unraveling the molecular etiology of lesch-Nyhan disease(LND). LND is a severe X-linked neurological disorder caused by a deficiency of hypoxanthine phosphoribosyltransferase. PRTFDC1 has a low, barely measurable phosphoribosyltransferase activity (in vitro).

References

Welin M. et al., 2010, FEBS J. 277 (23): 4920-30.
Keebaugh AC. et al., 2011, PLoS One. 6 (7): e22381.
Suzuki E. et al., 2007, Oncogene. 26 (57): 7921-32.